Lung Cancer Therapeutics Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer); Molecule Type (Small molecules, Biologics)
Report Code: TIPRE00004083 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Lung Cancer is a disease that involves uncontrolled cell growth in the lungs, which decreases the ability of lungs to provide oxygen into the bloodstream increasing the tumor or cell growth. The major symptoms are body mucus, chest pain, weight loss and coughing.
MARKET DYNAMICS
The Lung Cancer Therapeutics Market is anticipated to grow in the forecast period owing to driving factors such as rising demand for targeted therapies, rising incidence of Lung Cancer due to rising smoking population, launch of premium priced drugs and new innovation radiation therapies. Nevertheless, genericization of the major drugs and adverse effects of chemotherapy may restrain the market growth during the forecasted period.
MARKET SCOPE
The "Global Lung Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Lung Cancer Therapeutics Market with detailed market segmentation by Disease Type, Molecule Type and Geography. The global Lung Cancer Therapeutics Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Lung Cancer Therapeutics Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Lung Cancer Therapeutics Market is segmented on the basis of Disease Type and Molecule Type. Based on Disease Type the market is segmented into Non-Small Cell Lung Cancer, Small Cell Lung Cancer. Based on Molecule Type the market is segmented into Small molecules, Biologics. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Lung Cancer Therapeutics Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Lung Cancer Therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Lung Cancer Therapeutics Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Lung Cancer Therapeutics Market in these regions.
MARKET PLAYERS
The reports cover key developments in the Lung Cancer Therapeutics Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Lung Cancer Therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for Lung Cancer Therapeutics Market in the global market. Below mentioned is the list of few companies engaged in the Lung Cancer Therapeutics Market.
The report also includes the profiles of key Lung Cancer Therapeutics Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Lung Cancer is a disease that involves uncontrolled cell growth in the lungs, which decreases the ability of lungs to provide oxygen into the bloodstream increasing the tumor or cell growth. The major symptoms are body mucus, chest pain, weight loss and coughing.
MARKET DYNAMICS
The Lung Cancer Therapeutics Market is anticipated to grow in the forecast period owing to driving factors such as rising demand for targeted therapies, rising incidence of Lung Cancer due to rising smoking population, launch of premium priced drugs and new innovation radiation therapies. Nevertheless, genericization of the major drugs and adverse effects of chemotherapy may restrain the market growth during the forecasted period.
MARKET SCOPE
The "Global Lung Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Lung Cancer Therapeutics Market with detailed market segmentation by Disease Type, Molecule Type and Geography. The global Lung Cancer Therapeutics Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Lung Cancer Therapeutics Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Lung Cancer Therapeutics Market is segmented on the basis of Disease Type and Molecule Type. Based on Disease Type the market is segmented into Non-Small Cell Lung Cancer, Small Cell Lung Cancer. Based on Molecule Type the market is segmented into Small molecules, Biologics. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Lung Cancer Therapeutics Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Lung Cancer Therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Lung Cancer Therapeutics Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Lung Cancer Therapeutics Market in these regions.
MARKET PLAYERS
The reports cover key developments in the Lung Cancer Therapeutics Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Lung Cancer Therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for Lung Cancer Therapeutics Market in the global market. Below mentioned is the list of few companies engaged in the Lung Cancer Therapeutics Market.
The report also includes the profiles of key Lung Cancer Therapeutics Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Astellas Pharma
- Pfizer
- Amgen
- Celgene
- AstraZeneca
- F. Hofmann-La Roche
- GlaxoSmithKline
- Aetna, Agennix
- Eli Lilly
- Boston Biomedical
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Lung Cancer Therapeutics Market - By Disease Type
1.3.2 Lung Cancer Therapeutics Market - By Molecule Type
1.3.3 Lung Cancer Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. LUNG CANCER THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LUNG CANCER THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. LUNG CANCER THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. LUNG CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. LUNG CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. NON-SMALL CELL LUNG CANCER
7.3.1. Overview
7.3.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
7.4. SMALL CELL LUNG CANCER
7.4.1. Overview
7.4.2. Small Cell Lung Cancer Market Forecast and Analysis
8. LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - MOLECULE TYPE
8.1. OVERVIEW
8.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
8.3. SMALL MOLECULES
8.3.1. Overview
8.3.2. Small molecules Market Forecast and Analysis
8.4. BIOLOGICS
8.4.1. Overview
8.4.2. Biologics Market Forecast and Analysis
9. LUNG CANCER THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Lung Cancer Therapeutics Market Overview
9.1.2 North America Lung Cancer Therapeutics Market Forecasts and Analysis
9.1.3 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.1.4 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.1.5 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Lung Cancer Therapeutics Market
9.1.5.1.1 United States Lung Cancer Therapeutics Market by Disease Type
9.1.5.1.2 United States Lung Cancer Therapeutics Market by Molecule Type
9.1.5.2 Canada Lung Cancer Therapeutics Market
9.1.5.2.1 Canada Lung Cancer Therapeutics Market by Disease Type
9.1.5.2.2 Canada Lung Cancer Therapeutics Market by Molecule Type
9.1.5.3 Mexico Lung Cancer Therapeutics Market
9.1.5.3.1 Mexico Lung Cancer Therapeutics Market by Disease Type
9.1.5.3.2 Mexico Lung Cancer Therapeutics Market by Molecule Type
9.1.5.4 US Lung Cancer Therapeutics Market
9.1.5.4.1 US Lung Cancer Therapeutics Market by Disease Type
9.1.5.4.2 US Lung Cancer Therapeutics Market by Molecule Type
9.2. EUROPE
9.2.1 Europe Lung Cancer Therapeutics Market Overview
9.2.2 Europe Lung Cancer Therapeutics Market Forecasts and Analysis
9.2.3 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.2.5 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Lung Cancer Therapeutics Market
9.2.5.1.1 Germany Lung Cancer Therapeutics Market by Disease Type
9.2.5.1.2 Germany Lung Cancer Therapeutics Market by Molecule Type
9.2.5.2 France Lung Cancer Therapeutics Market
9.2.5.2.1 France Lung Cancer Therapeutics Market by Disease Type
9.2.5.2.2 France Lung Cancer Therapeutics Market by Molecule Type
9.2.5.3 Italy Lung Cancer Therapeutics Market
9.2.5.3.1 Italy Lung Cancer Therapeutics Market by Disease Type
9.2.5.3.2 Italy Lung Cancer Therapeutics Market by Molecule Type
9.2.5.4 Spain Lung Cancer Therapeutics Market
9.2.5.4.1 Spain Lung Cancer Therapeutics Market by Disease Type
9.2.5.4.2 Spain Lung Cancer Therapeutics Market by Molecule Type
9.2.5.5 United Kingdom Lung Cancer Therapeutics Market
9.2.5.5.1 United Kingdom Lung Cancer Therapeutics Market by Disease Type
9.2.5.5.2 United Kingdom Lung Cancer Therapeutics Market by Molecule Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Lung Cancer Therapeutics Market Overview
9.3.2 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.3.5 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Lung Cancer Therapeutics Market
9.3.5.1.1 Australia Lung Cancer Therapeutics Market by Disease Type
9.3.5.1.2 Australia Lung Cancer Therapeutics Market by Molecule Type
9.3.5.2 China Lung Cancer Therapeutics Market
9.3.5.2.1 China Lung Cancer Therapeutics Market by Disease Type
9.3.5.2.2 China Lung Cancer Therapeutics Market by Molecule Type
9.3.5.3 India Lung Cancer Therapeutics Market
9.3.5.3.1 India Lung Cancer Therapeutics Market by Disease Type
9.3.5.3.2 India Lung Cancer Therapeutics Market by Molecule Type
9.3.5.4 Japan Lung Cancer Therapeutics Market
9.3.5.4.1 Japan Lung Cancer Therapeutics Market by Disease Type
9.3.5.4.2 Japan Lung Cancer Therapeutics Market by Molecule Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Lung Cancer Therapeutics Market Overview
9.4.2 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.4.5 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Lung Cancer Therapeutics Market
9.4.5.1.1 South Africa Lung Cancer Therapeutics Market by Disease Type
9.4.5.1.2 South Africa Lung Cancer Therapeutics Market by Molecule Type
9.4.5.2 Saudi Arabia Lung Cancer Therapeutics Market
9.4.5.2.1 Saudi Arabia Lung Cancer Therapeutics Market by Disease Type
9.4.5.2.2 Saudi Arabia Lung Cancer Therapeutics Market by Molecule Type
9.4.5.3 U.A.E Lung Cancer Therapeutics Market
9.4.5.3.1 U.A.E Lung Cancer Therapeutics Market by Disease Type
9.4.5.3.2 U.A.E Lung Cancer Therapeutics Market by Molecule Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Lung Cancer Therapeutics Market Overview
9.5.2 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.5.5 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Lung Cancer Therapeutics Market
9.5.5.1.1 Brazil Lung Cancer Therapeutics Market by Disease Type
9.5.5.1.2 Brazil Lung Cancer Therapeutics Market by Molecule Type
9.5.5.2 Argentina Lung Cancer Therapeutics Market
9.5.5.2.1 Argentina Lung Cancer Therapeutics Market by Disease Type
9.5.5.2.2 Argentina Lung Cancer Therapeutics Market by Molecule Type
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LUNG CANCER THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. ASTELLAS PHARMA
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. PFIZER
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. AMGEN
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CELGENE
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ASTRAZENECA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. F. HOFMANN-LA ROCHE
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GLAXOSMITHKLINE
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. AETNA
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ELI LILLY
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. BOSTON BIOMEDICAL
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Lung Cancer Therapeutics Market - By Disease Type
1.3.2 Lung Cancer Therapeutics Market - By Molecule Type
1.3.3 Lung Cancer Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. LUNG CANCER THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LUNG CANCER THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. LUNG CANCER THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. LUNG CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. LUNG CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. NON-SMALL CELL LUNG CANCER
7.3.1. Overview
7.3.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
7.4. SMALL CELL LUNG CANCER
7.4.1. Overview
7.4.2. Small Cell Lung Cancer Market Forecast and Analysis
8. LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - MOLECULE TYPE
8.1. OVERVIEW
8.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
8.3. SMALL MOLECULES
8.3.1. Overview
8.3.2. Small molecules Market Forecast and Analysis
8.4. BIOLOGICS
8.4.1. Overview
8.4.2. Biologics Market Forecast and Analysis
9. LUNG CANCER THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Lung Cancer Therapeutics Market Overview
9.1.2 North America Lung Cancer Therapeutics Market Forecasts and Analysis
9.1.3 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.1.4 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.1.5 North America Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Lung Cancer Therapeutics Market
9.1.5.1.1 United States Lung Cancer Therapeutics Market by Disease Type
9.1.5.1.2 United States Lung Cancer Therapeutics Market by Molecule Type
9.1.5.2 Canada Lung Cancer Therapeutics Market
9.1.5.2.1 Canada Lung Cancer Therapeutics Market by Disease Type
9.1.5.2.2 Canada Lung Cancer Therapeutics Market by Molecule Type
9.1.5.3 Mexico Lung Cancer Therapeutics Market
9.1.5.3.1 Mexico Lung Cancer Therapeutics Market by Disease Type
9.1.5.3.2 Mexico Lung Cancer Therapeutics Market by Molecule Type
9.1.5.4 US Lung Cancer Therapeutics Market
9.1.5.4.1 US Lung Cancer Therapeutics Market by Disease Type
9.1.5.4.2 US Lung Cancer Therapeutics Market by Molecule Type
9.2. EUROPE
9.2.1 Europe Lung Cancer Therapeutics Market Overview
9.2.2 Europe Lung Cancer Therapeutics Market Forecasts and Analysis
9.2.3 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.2.5 Europe Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Lung Cancer Therapeutics Market
9.2.5.1.1 Germany Lung Cancer Therapeutics Market by Disease Type
9.2.5.1.2 Germany Lung Cancer Therapeutics Market by Molecule Type
9.2.5.2 France Lung Cancer Therapeutics Market
9.2.5.2.1 France Lung Cancer Therapeutics Market by Disease Type
9.2.5.2.2 France Lung Cancer Therapeutics Market by Molecule Type
9.2.5.3 Italy Lung Cancer Therapeutics Market
9.2.5.3.1 Italy Lung Cancer Therapeutics Market by Disease Type
9.2.5.3.2 Italy Lung Cancer Therapeutics Market by Molecule Type
9.2.5.4 Spain Lung Cancer Therapeutics Market
9.2.5.4.1 Spain Lung Cancer Therapeutics Market by Disease Type
9.2.5.4.2 Spain Lung Cancer Therapeutics Market by Molecule Type
9.2.5.5 United Kingdom Lung Cancer Therapeutics Market
9.2.5.5.1 United Kingdom Lung Cancer Therapeutics Market by Disease Type
9.2.5.5.2 United Kingdom Lung Cancer Therapeutics Market by Molecule Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Lung Cancer Therapeutics Market Overview
9.3.2 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.3.5 Asia-Pacific Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Lung Cancer Therapeutics Market
9.3.5.1.1 Australia Lung Cancer Therapeutics Market by Disease Type
9.3.5.1.2 Australia Lung Cancer Therapeutics Market by Molecule Type
9.3.5.2 China Lung Cancer Therapeutics Market
9.3.5.2.1 China Lung Cancer Therapeutics Market by Disease Type
9.3.5.2.2 China Lung Cancer Therapeutics Market by Molecule Type
9.3.5.3 India Lung Cancer Therapeutics Market
9.3.5.3.1 India Lung Cancer Therapeutics Market by Disease Type
9.3.5.3.2 India Lung Cancer Therapeutics Market by Molecule Type
9.3.5.4 Japan Lung Cancer Therapeutics Market
9.3.5.4.1 Japan Lung Cancer Therapeutics Market by Disease Type
9.3.5.4.2 Japan Lung Cancer Therapeutics Market by Molecule Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Lung Cancer Therapeutics Market Overview
9.4.2 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.4.5 Middle East and Africa Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Lung Cancer Therapeutics Market
9.4.5.1.1 South Africa Lung Cancer Therapeutics Market by Disease Type
9.4.5.1.2 South Africa Lung Cancer Therapeutics Market by Molecule Type
9.4.5.2 Saudi Arabia Lung Cancer Therapeutics Market
9.4.5.2.1 Saudi Arabia Lung Cancer Therapeutics Market by Disease Type
9.4.5.2.2 Saudi Arabia Lung Cancer Therapeutics Market by Molecule Type
9.4.5.3 U.A.E Lung Cancer Therapeutics Market
9.4.5.3.1 U.A.E Lung Cancer Therapeutics Market by Disease Type
9.4.5.3.2 U.A.E Lung Cancer Therapeutics Market by Molecule Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Lung Cancer Therapeutics Market Overview
9.5.2 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Molecule Type
9.5.5 South and Central America Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Lung Cancer Therapeutics Market
9.5.5.1.1 Brazil Lung Cancer Therapeutics Market by Disease Type
9.5.5.1.2 Brazil Lung Cancer Therapeutics Market by Molecule Type
9.5.5.2 Argentina Lung Cancer Therapeutics Market
9.5.5.2.1 Argentina Lung Cancer Therapeutics Market by Disease Type
9.5.5.2.2 Argentina Lung Cancer Therapeutics Market by Molecule Type
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LUNG CANCER THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. ASTELLAS PHARMA
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. PFIZER
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. AMGEN
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CELGENE
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ASTRAZENECA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. F. HOFMANN-LA ROCHE
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GLAXOSMITHKLINE
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. AETNA
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ELI LILLY
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. BOSTON BIOMEDICAL
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Astellas Pharma
2. Pfizer
3. Amgen
4. Celgene
5. AstraZeneca
6. F. HofmannLa Roche
7. GlaxoSmithKline
8. Aetna, Agennix
9. Eli Lilly
10. Boston Biomedical
1. Astellas Pharma
2. Pfizer
3. Amgen
4. Celgene
5. AstraZeneca
6. F. HofmannLa Roche
7. GlaxoSmithKline
8. Aetna, Agennix
9. Eli Lilly
10. Boston Biomedical